Olivier HARISMENDY, PhD

Assistant Professor


Research Statement

My research program is focused on the identification of genetic and epigenetic markers for cancer prevention, progression as well as drug response. The laboratory is a humid laboratory, combining both wet-lab techniques and bioinformatics analysis to study cancer samples from patients and animal models of cancer. I have more than 18 years of experience generating and analyzing genomic data from chromatin, transcriptome, and resequencing projects, applying them to translational cancer research for the past 10 years. I evaluated the different Next Generation Sequencing technologies for their use in targeted sequencing to identify human DNA variants, both generating the data and performing the bioinformatics analysis. I have also played a key role in the development of targeted sequencing methods such as exome sequencing. I applied these technologies to profile the mutational landscape of glioblastoma, appendix cancer, mesothelioma, gastro-intestinal stromal tumors and leukemia, as well as to support clinical diagnostics through the development of the Ultra Deep targeted sequencing (UDT-Seq) assay. My current research focuses on the identification of biomarkers and therapeutic targets for 1) carboplatin resistance in ovarian cancer, and 2) progression of pre-malignant lesions in Oral squamous Cell carcinoma (M4O-prevent trial) and breast cancer (Molecular and Cellular Lesion - NCI Consortium), both using combinations of bulk and single cell molecular profiling associated with multidimensional reduction methods. I lead several data stewardship efforts: implementation of clinical genetics data sharing, reporting and analytics for the cancer center biorepository, and construction of the breast DCIS registry.